Insider Trading Alert - ERA, HDSN And BIOA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, May 8, 2015, 68 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,023.75 to $5,610,306.91.

Highlighted Stocks Traded by Insiders:

Era Group (ERA) - FREE Research Report

White Paul T, who is SVP - Commercial at Era Group, sold 7,622 shares at $21.89 on May 8, 2015. Following this transaction, the SVP - Commercial owned 24,001 shares meaning that the stake was reduced by 24.1% with the 7,622-share transaction.

The shares most recently traded at $22.05, up $0.16, or 0.71% since the insider transaction. Historical insider transactions for Era Group go as follows:

  • 4-Week # shares bought: 2,100
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 2,100
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 2,100
  • 24-Week # shares sold: 20,000

The average volume for Era Group has been 112,100 shares per day over the past 30 days. Era Group has a market cap of $445.6 million and is part of the services sector and transportation industry. Shares are up 2.36% year-to-date as of the close of trading on Friday.

Era Group Inc. provides helicopter transportation services primarily to the oil and gas exploration, development, and production companies. The company has a P/E ratio of 34.9. Currently, there are no analysts who rate Era Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ERA - FREE

TheStreet Quant Ratings rates Era Group as a hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, feeble growth in the company's earnings per share and deteriorating net income. Get the full Era Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Hudson Technologies (HDSN) - FREE Research Report

Harkins Charles F, who is Vice President Sales at Hudson Technologies, sold 45,429 shares at $3.87 on May 8, 2015. Following this transaction, the Vice President Sales owned 160,000 shares meaning that the stake was reduced by 22.11% with the 45,429-share transaction.

The shares most recently traded at $4.03, up $0.16, or 3.97% since the insider transaction. Historical insider transactions for Hudson Technologies go as follows:

  • 4-Week # shares sold: 148,585
  • 12-Week # shares sold: 148,585
  • 24-Week # shares sold: 161,085

The average volume for Hudson Technologies has been 89,400 shares per day over the past 30 days. Hudson Technologies has a market cap of $128.5 million and is part of the industrial goods sector and industrial industry. Shares are up 5.3% year-to-date as of the close of trading on Friday.

Hudson Technologies, Inc. operates as a refrigerant services company that provides solutions to the refrigeration industry in the United States and internationally. The company has a P/E ratio of 132.3. Currently, there are 3 analysts who rate Hudson Technologies a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HDSN - FREE

TheStreet Quant Ratings rates Hudson Technologies as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full Hudson Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BioAmber (BIOA) - FREE Research Report

Briner Kurt W, who is Director at BioAmber, bought 10,000 shares at $9.00 on May 8, 2015. Following this transaction, the Director owned 80,630 shares meaning that the stake was boosted by 14.16% with the 10,000-share transaction.

Haller Heinz, who is Director at BioAmber, bought 10,000 shares at $9.00 on May 8, 2015. Following this transaction, the Director owned 10,000 shares meaning that the stake was boosted by 100% with the 10,000-share transaction.

Millis James, who is Chief Technology Officer at BioAmber, bought 1,100 shares at $9.00 on May 8, 2015. Following this transaction, the Chief Technology Officer owned 1,100 shares meaning that the stake was boosted by 100% with the 1,100-share transaction.

Orecchioni Fabrice, who is Chief Operations Officer at BioAmber, bought 1,100 shares at $9.00 on May 8, 2015. Following this transaction, the Chief Operations Officer owned 1,100 shares meaning that the stake was boosted by 100% with the 1,100-share transaction.

Laurin Francois, who is Chief Financial Officer at BioAmber, bought 2,200 shares at $9.00 on May 8, 2015. Following this transaction, the Chief Financial Officer owned 12,200 shares meaning that the stake was boosted by 22% with the 2,200-share transaction.

The shares most recently traded at $8.66, down $0.34, or 3.93% since the insider transaction. Historical insider transactions for BioAmber go as follows:

  • 4-Week # shares bought: 3,000
  • 12-Week # shares bought: 3,000
  • 24-Week # shares bought: 8,000

The average volume for BioAmber has been 77,200 shares per day over the past 30 days. BioAmber has a market cap of $185.2 million and is part of the basic materials sector and chemicals industry. Shares are up 1.07% year-to-date as of the close of trading on Friday.

BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various chemical market customers in the United States. The company has a P/E ratio of 3.7. Currently, there are 2 analysts who rate BioAmber a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIOA - FREE

TheStreet Quant Ratings rates BioAmber as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full BioAmber Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday